Uveal melanoma (UM) is the most common intraocular malignant carcinoma. This study aimed to compare the clinical features, treatment modalities, and prognosis of UM patients in China with those in America over a 15-year period. In the study, 4088 American patients with primary UM from the Surveillance, Epidemiology, and End Results (SEER) database and 1508 Chinese patients from Tongren-ophthalmology Research Association of Clinical Evaluation (TRACE) were included. Univariable and multivariable analyses were performed to determine prognostic factors and propensity score matching (PSM) and sensitivity analyses were applied to adjust for confounders and identify independent prognostic factors. Chinese patients were diagnosed at a younger age (mean ± SD, 47.3 ± 12.5 years vs. 59.7 ± 14.8 years) and tumors at diagnosis were larger (diameter: 12.0 ± 3.54 mm vs. 11.3 ± 8.27 mm; thickness: 7.13 ± 3.28 mm vs. 4.91 ± 3.01 mm). Chinese patients were more likely to undergo brachytherapy than American patients. Chinese patients had better overall survival than American patients while no significant differences exhibited after adjusting for age through PSM. In conclusion, compared with American patients, Chinese patients had younger onset age, larger tumors at diagnosis and better prognosis, mainly because of their younger age.
These lack a thorough comparison of swept-source optical coherence tomography (SS-OCT) features among different kinds of choroidal tumors and tumor mimics. This retrospective case series study based on 305 eyes from 298 consecutive patients with choroidal tumors or tumor mimics treated at Beijing Tongren Hospital between July 2019 and March 2024. The diagnostic performance of SS-OCT features in distinguishing malignant tumors were evaluated. The present study included choroidal melanoma (n = 113), choroidal lymphoma (n = 11), choroidal metastasis (n = 9), choroidal hemangioma (n = 92), choroidal nevus (n = 9), choroidal osteoma (n = 32), RPE adenoma (n = 4), choroidal tuberculoma (n = 2), posterior scleritis (n = 2), and choroidal leiomyoma (n = 1). The median thickness and largest basal diameter were 2.9 mm (interquartile range: 2.0-4.2) and 9.0 mm (interquartile range: 5.7-11.3). Among all SS-OCT features, multivariable logistic regression showed optical shadowing (Odds Ratio [OR]=104.1, 95 %CI: 5.33-2028.8), subretinal fluid (3 mm from margin: OR=24.2, 95 %CI: 2.14-274.0), and overlying choriocapillaris complete loss (OR=52.3, 95 %CI: 4.85-552.7) highly indicated malignant choroidal tumor. Choriocapillaris loss was more sensitive (0.962, 95 %CI: 0.926-0.992) in identifying malignant tumors than optical shadowing (0.791, 95 %CI: 0.730-0.850) and subretinal fluid >3 mm from the tumor margin (0.714, 95 %CI: 0.639-0.788). Choriocapillaris loss also showed high sensitivity (0.923, 95 %CI: 0.919-1.000) and specificity (0.973, 95 %CI: 0.940-1.000) in identifying choroidal melanoma from choroidal nevus. The appearance of choriocapillaris loss or subretinal fluid >3 mm from the tumor margin showed 100 % sensitivity in identifying malignant amelanotic tumors. Choriocapillaris loss, optical shadowing, and extensive subretinal fluid can be used to identify malignant tumors.
To examine if pregnancy affects the prognosis of uveal melanoma (UM) patients undergoing plaque brachytherapy (PBT) and to assess if PBT has any subsequent impact on pregnancy outcomes. A retrospective, single-center study was carried out at Beijing Tongren Hospital, focusing on women of childbearing age diagnosed with UM and treated with iodine-125 plaque brachytherapy. Both the outcomes of pregnancies and the health status of the fetuses were monitored. Survival analyses were conducted using the Kaplan-Meier method, with endpoints being metastasis and death. A total of 13 patients who had full-term pregnancies and 96 non-pregnant women matched by age and tumor size were included. The mean follow-up time was 67.0 ± 27.7 months (median:66.0 months, range:21.0 to 116.0 months). In the pregnant group, two patients developed metastases, one of whom died shortly after delivery; local recurrence of UM occurred in 2 patients after or during delivery, and 2 other patients developed secondary glaucoma due to radiation retinopathy. None of the other pregnant patients reported any signs of disease progression. In the control group, 18 metastasis cases including 12 deaths were documented. Pregnant patients and matched control subjects showed no statistical difference in both Metastasis-free survival (hazard ratio (HR): 0.66, 95% confidence interval (CI): 0.15–2.86; P = 0.576) and overall survival (HR: 0.48, 95% CI: 0.06–3.66; P = 0.464). All pregnant patients carried the pregnancy to term and delivered healthy children with no report of placental or infant metastases to date. Pregnancy does not appear to negatively impact the prognosis of UM patients undergoing PBT. PBT showed no observable detriment to maternal fertility and exhibited no teratogenic effects on the fetus. However, the long-term implications of PBT on pregnancy remain uncertain, necessitating additional, prolonged follow-up studies.